Asian Journal of Andrology

INVITED RESEARCH HIGHLIGHT
Year
: 2015  |  Volume : 17  |  Issue : 3  |  Page : 439--440

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer


Oliver Sartor1, Yan Dong2 
1 Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA
2 Department of Structural and Cellular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA; National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, Changchun, Jilin, China

Correspondence Address:
Oliver Sartor
Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA

Yan Dong
Department of Structural and Cellular Biology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA; National Engineering Laboratory for AIDS Vaccine, College of Life Sciences, Jilin University, Changchun, Jilin, China

The recent manuscript in New England Journal of Medicine by Antonarakis et al. [1] has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses. Further, the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3-1.4 months in AR-V7-positive patients as compared to 5.3-6.1 months in AR-V7 negative patients. AR-V7 in CTCs was also associated with shorter survival.


How to cite this article:
Sartor O, Dong Y. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.Asian J Androl 2015;17:439-440


How to cite this URL:
Sartor O, Dong Y. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer. Asian J Androl [serial online] 2015 [cited 2022 Aug 13 ];17:439-440
Available from: https://www.ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=3;spage=439;epage=440;aulast=Sartor;type=0